Pfizer, Beqvez and gene therapy
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...
Weak demand for Pfizer’s hemophilia gene therapy Beqvez has led the pharmaceutical company to “cease further development and commercialization” of the one-time treatment, a Pfizer ...
Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback